Table 2.
Characteristics of studies evaluating depression treatments in a cancer population (N=84)
| N (%) | |
| Study type | |
| Randomised controlled trial | 38 (45) |
| Non-controlled trial | 26 (31) |
| Feasibility or pilot | 1 (1) |
| Case series | 4 (5) |
| Case report | 15 (18) |
| Method of depression diagnosis | |
| Interview | 44 (52) |
| Self-report instrument | 26 (31) |
| Both | 14 (17) |
| Intervention | |
| Pharmacotherapy | 39 (46) |
| Psychological | 43 (51) |
| Both | 2 (3) |
| Cancer type* | |
| Brain, central nervous system | 12 (0.2) |
| Haematopoietic, lymphoid | 295 (4.9) |
| Mesenchymal | 53 (0.9) |
| Lip, oral cavity, pharynx | 183 (3) |
| Digestive organs | 680 (11.2) |
| Middle ear, respiratory, intrathoracic organs | 701 (11.6) |
| Skin | 40 (0.7) |
| Peripheral nerve, autonomic nervous system | 4 (0.1) |
| Retroperitoneum, peritoneum, omentum | 4 (0.1) |
| Breast | 2983 (49.3) |
| Female genital organs | 375 (6.2) |
| Male genital organs | 89 (1.5) |
| Urinary tract | 189 (3.1) |
| Eye, ocular adnexa | 0 (0) |
| Endocrine glands | 18 (0.3) |
| Ill-defined sites (eg, neuroendocrine), unknown primary | 14 (0.2) |
| ‘Other’ | 408 (6.7) |
*Classified according to ICD-11 topographic clusters.